Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer

• Published in: International journal of cancer Vol. 121; no. 11; pp. 2575 - 2577
• Main Authors: Fennell, Dean A., Steele, Jeremy P.C., Shamash, Jonathan, Slater, Sarah E., Sheaff, Michael T., Wells, Paula, Rudd, Robin M., Stebbing, Justin
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.12.2007; Wiley-Liss
• Subjects: Adult; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Carcinoma, Small Cell - drug therapy; Carcinoma, Small Cell - pathology; Chemotherapy; cisplatin; Cisplatin - administration & dosage; Drug Administration Schedule; Female; Humans; irinotecan; Kaplan-Meier Estimate; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Medical sciences; Middle Aged; mitomycin; Mitomycin - administration & dosage; Neoplasm Recurrence, Local - drug therapy; Pharmacology. Drug treatments; phase II clinical trial; Quality of Life; relapsed; second‐line; small cell lung cancer; Tomography, X-Ray Computed; Treatment Outcome; triplet; Tumors; Antineoplastic agent; triplet; Relapse; Prognosis; Lung cancer; Bonchopulmonary small cell carcinoma; Isomerases; Cancerology; Phase II trial; Progression free survival; Bronchus disease; small cell lung cancer; Platinum II Complexes; Human; Lung disease; Drug combination; Mitomycin; second-line; Respiratory disease; Enzyme; DNA topoisomerase; phase II clinical trial; Enzyme inhibitor; Malignant tumor; Cisplatin; Irinotecan; Alkylating agent; Chemotherapy; Treatment; relapsed
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/ijc.22984

There is no standard therapy for relapsed small cell lung cancer (rSCLC). We evaluated the efficacy and toxicity of a new triplet consisting of irinotecan (100 mg/m2 Days 1 and 15 q28), cisplatin (40 mg/m2 Days 1 and 15 q28) and mitomycin (6 mg/m2 d1 q28) administered to a maximum of 6 cycles in individuals with rSCLC that had relapsed following first line treatment. Partial remisions were observed in 35% and progression in 30% of patients. Progression free survival measured 4.5 months (95% CI 0.8–8.2) and overall survival was 7.8 months (95% CI 5.3–10.3). QoL showed improvement in activity symptoms and stabilization of physical symptoms. As IPM was a well‐tolerated regimen with activity in rSCLC, a phase III trial comparing this triplet with other regimens in this setting is warranted. © 2007 Wiley‐Liss, Inc.